DDInter1939 DDInter255
Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-generation drugs (vinorelbine, gemcitabine, taxanes) in platinum combination improved survival of patients with advanced NSCLC, with very similar results from the various drugs. Treatment toxicities are considerable in the combination treatment setting. A study was done on the clearance rate of vinorelbine on individuals with various single polymorphonuclear mutations. It was found that there was 4.3-fold variation in vinorelbine clearance across the cohort, suggesting a strong influence of genetics on the clearance of this drug.
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
Vinorelbine {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Busulfan
Vinorelbine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Busulfan
Vinorelbine {u} (Compound) downregulates {v} (Gene) MCM2
MCM2 {u} (Gene) is upregulated by {v} (Compound) Busulfan
Vinorelbine {u} (Compound) upregulates {v} (Gene) AXIN1
AXIN1 {u} (Gene) is upregulated by {v} (Compound) Busulfan
Vinorelbine {u} (Compound) upregulates {v} (Gene) DNAJB2
DNAJB2 {u} (Gene) is downregulated by {v} (Compound) Busulfan
Vinorelbine {u} (Compound) downregulates {v} (Gene) SPR
SPR {u} (Gene) is downregulated by {v} (Compound) Busulfan
Vinorelbine {u} (Compound) causes {v} (Side Effect) Dermatitis bullous
Dermatitis bullous {u} (Side Effect) is caused by {v} (Compound) Busulfan
Vinorelbine {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is associated with {v} (Gene) GSTM1
GSTM1 {u} (Gene) is bound by {v} (Compound) Busulfan
Vinorelbine {u} (Compound) downregulates {v} (Gene) MCM2
MCM2 {u} (Gene) is regulated by {v} (Gene) GPER1
GPER1 {u} (Gene) is upregulated by {v} (Compound) Busulfan
Vinorelbine {u} (Compound) downregulates {v} (Gene) SLC35A1
SLC35A1 {u} (Gene) regulates {v} (Gene) GPER1
GPER1 {u} (Gene) is upregulated by {v} (Compound) Busulfan
Vinorelbine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Busulfan (Compound)
Vinorelbine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Busulfan (Compound)
Vinorelbine (Compound) downregulates MCM2 (Gene) and MCM2 (Gene) is upregulated by Busulfan (Compound)
Vinorelbine (Compound) upregulates AXIN1 (Gene) and AXIN1 (Gene) is upregulated by Busulfan (Compound)
Vinorelbine (Compound) upregulates DNAJB2 (Gene) and DNAJB2 (Gene) is downregulated by Busulfan (Compound)
Vinorelbine (Compound) downregulates SPR (Gene) and SPR (Gene) is downregulated by Busulfan (Compound)
Vinorelbine (Compound) causes Dermatitis bullous (Side Effect) and Dermatitis bullous (Side Effect) is caused by Busulfan (Compound)
Vinorelbine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is associated with GSTM1 (Gene) and GSTM1 (Gene) is bound by Busulfan (Compound)
Vinorelbine (Compound) downregulates MCM2 (Gene) and MCM2 (Gene) is regulated by GPER1 (Gene) and GPER1 (Gene) is upregulated by Busulfan (Compound)
Vinorelbine (Compound) downregulates SLC35A1 (Gene) and SLC35A1 (Gene) regulates GPER1 (Gene) and GPER1 (Gene) is upregulated by Busulfan (Compound)